AZD1656
Phase 2- Indications
- Systemic lupus erythematosus, ANCA-associated vasculitis
Company intelligence / Profile preview
Conduit has a unique business model of acquiring Phase 1 clinical assets from pharmaceutical companies and advancing them through Phase 2 before seeking third-party license deals. Their pipeline includes AZD1656 (Glucokinase Activator) which has completed 20+ Phase I trials in over 1,000 patients and is Phase 2 ready for autoimmune disorders, and AZD5904 (Myeloperoxidase Inhibitor) which has completed Phase I trials for idiopathic male infertility.
2 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Conduit Pharmacy.